Valturna, manufactured and distributed by Novartis Pharmaceutical Corporation, is a high blood pressure medication that combines two powerful drugs into one tablet. Aliskerin (Tekturna) and valsartan are both popular blood pressure drugs developed by Novartis however the combination of the two has posed serious health risks for users. Complications due to this medication have patients filing Valturna lawsuits and seeking compensation from the pharmaceutical company.
Valturna has been shown to have increased risks of stroke, kidney impairment, hyperkalemia and renal complications. Studies show that this increased risk is largely due to the aliskerin (Tekturna) component of the medication.
ALTITUDE Clinical Trials
Novartis began a clinical trial to test the safety of Tekturna for use in diabetics and patients with kidney or renal impairments. After noticing a high increase in adverse effects such as stoke, renal problems and others, Novartis decided to discontinue the trials. Though Tekturna alone remains on the market, the FDA contraindicated the use of this medication for patients with diabetes that are currently taking angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). The combined use of these products greatly increases a patient’s risk of adverse effects. Tekturna is still approved for use by appropriate patients however all are warned of the potential dangers of kidney and renal complications.
Once the trials were discontinued, Novartis decided to make a voluntary recall on Valturna since half of the medication was not safe for users. On April 20, 2012, Novartis announced that they would be pulling Valturna from the shelves and that it would no longer be produced for distribution on the U.S. market. By July of that year, Valturna was no longer available.
Hundreds of users suffered severe and harmful side effects from using Valturna before it was removed from the market. Tekturna users are still noticing adverse effects from the medication and are encouraged to seek alternative options for medication.
Complications from Valturna include, but are not limited to, kidney problems, strokes, hyperkalemia, hypotension and renal complications. Kidney problems and stroke cause permanent damage and can leave patients troubled even after drug use has been discontinued.
Patients have filed class action lawsuits against Novartis seeking compensation for their injuries as well as medical costs and recovery treatments. Patients with any history of renal complications, diabetes or kidney problems should notify their physician before beginning Tekturna. If you have suffered adverse effects while using Valturna, you may be eligible for compensation. Contact an experienced attorney to review your options and see if you qualify.